{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:55:31Z","timestamp":1762865731594,"version":"3.38.0"},"reference-count":117,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780123813268"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1016\/b978-0-12-381326-8.00006-5","type":"book-chapter","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T09:11:19Z","timestamp":1290417079000},"page":"119-162","source":"Crossref","is-referenced-by-count":17,"title":["The Chemistry of Catechol-O-Methyltransferase Inhibitors"],"prefix":"10.1016","author":[{"given":"David A.","family":"Learmonth","sequence":"first","affiliation":[]},{"given":"L\u00e1szl\u00f3 E.","family":"Kiss","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0010","unstructured":"Ahlmark, M., B\u00e4ckstr\u00f6m, R., Luiro, A., Pystynen, J., and Tiainen, E. (2007). New pharmaceutical compounds. WO2007\/010085 A2."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-1983-30206","article-title":"A simple preparation of O-phospho-L-tyrosine","volume":"1","author":"Alewood","year":"1983","journal-title":"Synthesis"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00126839-200304040-00001","article-title":"Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans","volume":"4","author":"Almeida","year":"2003","journal-title":"Drugs in R&D"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0040","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/0091270003258666","article-title":"Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects","volume":"43","author":"Almeida","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0003-9861(60)90142-9","article-title":"The enzymic methylation of pyrogallol","volume":"87","author":"Archer","year":"1960","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0060","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.130.3378.800","article-title":"Inhibitor of O-methylation of epinephrine and norepinephrine in vitro and in vivo","volume":"130","author":"Axelrod","year":"1959","journal-title":"Science"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0070","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0021-9258(18)64730-1","article-title":"O-Methylation of catecholamines in vivo","volume":"233","author":"Axelrod","year":"1958","journal-title":"J. Biol. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0080","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0021-9258(18)64731-3","article-title":"Enzymatic O-methylation of epinephrine and other catechols","volume":"233","author":"Axelrod","year":"1958","journal-title":"J. Biol. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/jm00124a017","article-title":"Synthesis of some novel potent and selective inhibitors of catechol-O-methyltransferase","volume":"32","author":"B\u00e4ckstr\u00f6m","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0100","unstructured":"B\u00e4ckstr\u00f6m, R., Pystynen, J., Lotta, T., Ovaska, M., and Taskinen, J. (2002). Derivatives of naphthalene with COMT inhibiting activity. WO2002\/22551 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0110","unstructured":"B\u00e4ckstr\u00f6m, R.J., Heinola, K.E., Honkanen, E.J., Kaakola, S.K., Kairisalo, P.J., Linden, I.-B.Y., M\u00e4nnist\u00f6, P.T., Nissinen, E.A.O., Pohto, P., Pipurri, A.K., and Pystynen, J.J. (1990). Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same. US Patent 4,963,590."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0120","unstructured":"B\u00e4ckstr\u00f6m, R.J., Heinola, K.E., Honkanen, E.J., Kaakola, S.K., Kairisalo, P.J., Linden, I.-B.Y., M\u00e4nnist\u00f6, P.T., Nissinen, E.A.O., Pohto, P., Pipurri, A.K., and Pystynen, J.J. (1995). Pharmacologically active catechol derivatives. US Patent 5,446,194."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.130.3373.453","article-title":"Inhibition of O-methyltransferase by catechol and sensitization to epinephrine","volume":"130","author":"Bacq","year":"1959","journal-title":"Science"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0140","unstructured":"Bader, T., Furegati, M., and Jungmann, O. (2008). Novel crystalline forms of entacapone and production thereof. US2008\/0076825 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0150","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1016\/j.bmc.2005.05.069","article-title":"Synthesis and evaluation of bifunctional nitrocatechol inhibitors of pig liver catechol-O-methyltransferase","volume":"13","author":"Bailey","year":"2005","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0006-3002(61)90956-8","article-title":"Tropolones: a unique class of potent non-competitive inhibitors of S-adenosylmethionine-catechol methyltransferase","volume":"54","author":"Belleau","year":"1961","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1021\/jm00342a028","article-title":"Occupancy of adrenergic receptors and inhibition of catechol-O-methyltransferase by tropolones","volume":"6","author":"Belleau","year":"1963","journal-title":"J. Med. Chem"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0180","unstructured":"Bernauer, K., Borgulya, J., Bruderer, H., Da Prada, M., and Z\u00fcrcher, G. (1993). Catechol derivatives. US Patent 5,236,952."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0190","unstructured":"Bernauer, K., Borgulya, J., Bruderer, H., Da Prada, M., and Z\u00fcrcher, G. (1995a). Catechol derivatives. US Patent 5,389,653."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0200","unstructured":"Bernauer, K., Borgulya, J., Bruderer, H., Da Prada, M., and Z\u00fcrcher, G. (1995b). Catechol derivatives. US Patent 5,476,875."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0210","unstructured":"Bernauer, K., Borgulya, J., Bruderer, H., Da Prada, M., and Z\u00fcrcher, G. (1997). Catechol derivatives. US Patent 5,633,371."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0220","unstructured":"Bernauer, K., Borgulya, J., Bruderer, H., Da Prada, M., and Z\u00fcrcher, G. (1998). Catechol derivatives. US Patent 5,705,703."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0230","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/mol.62.4.795","article-title":"Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application","volume":"62","author":"Bonif\u00e1cio","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(02)02879-0","article-title":"Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor","volume":"460","author":"Bonif\u00e1cio","year":"2003","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0250","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/S0021-9258(18)69715-7","article-title":"The metabolic fate of gallic acid and related compounds","volume":"234","author":"Booth","year":"1959","journal-title":"J. Biol. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0260","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/jm00263a047","article-title":"Catechol-O-methyltransferase. 4. In vitro inhibition by 3-hydroxy-4-pyrones, 3-hydroxy-2-pyridones and 3-hydroxy-4-pyridones","volume":"16","author":"Borchardt","year":"1973","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0270","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/jm00262a016","article-title":"Catechol-O-methyltransferase. 2. In vitro inhibition by substituted 8-hydroxyquinolines","volume":"16","author":"Borchardt","year":"1973","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: liver toxicity and clinical efficacy","volume":"41","author":"Borges","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0290","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/hlca.19890720511","article-title":"Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure\u2013activity studies","volume":"72","author":"Borgulya","year":"1989","journal-title":"Helv Chim. Acta"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1358\/dof.1991.016.08.142757","article-title":"Ro40-7592 (3,4-dihydroxy-4\u2032-methyl-5-nitrobenzophenone), catecholamine-O-methyltransferase (COMT) inhibitor","volume":"16","author":"Borgulya","year":"1991","journal-title":"Drugs Future"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0310","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1021\/jm9605187","article-title":"Synthesis and in vitro evaluation of two progressive series of bifunctional polyhdroxybenzamide catechol-O-methyltransferase inhibitors","volume":"40","author":"Brevitt","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0320","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0773.1973.tb01543.x","article-title":"The in vivo effect of tropolone on noradrenaline metabolism and catechol-O-methyltransferase activity in the striatum of the rat","volume":"33","author":"Broch","year":"1973","journal-title":"Acta Pharmacol. Toxicol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0330","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1021\/jm00008a017","article-title":"Conformationally restrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors","volume":"38","author":"Burke","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0340","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.bcp.2005.01.024","article-title":"Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular modeling studies","volume":"69","author":"Chen","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0350","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0022-3565(25)26042-6","article-title":"Norepinephrine metabolism in rat brain and heart","volume":"132","author":"Crout","year":"1961","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0360","unstructured":"Despande, P.B., Luthra, P.K., Pandey, A.K., and Darmesh, D.R. (2006). Process for the preparation of (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide (entacapone). US2006\/0258877 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0370","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/(SICI)1099-1344(199704)39:4<303::AID-JLCR977>3.0.CO;2-W","article-title":"Synthesis of [18F]-Ro41-0960, a potent catechol-O-methyltransferase inhibitor, for PET studies","volume":"39","author":"Ding","year":"1997","journal-title":"J. Labelled Comp. Radiopharm."},{"issue":"Suppl. 15","key":"10.1016\/B978-0-12-381326-8.00006-5_bib0380","first-page":"S644","article-title":"A double-blind, randomised, placebo- and entacapone-controlled study to investigate the effect of nebicapone (BIA 3-202) on the levodopa pharmacokinetics, COMT activity and motor response in Parkinson disease patients","volume":"21","author":"Ferreira","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0390","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)27782-5","article-title":"The catechol-O-methyltransferase activity and endogenous catecholamine content of various tissues in the rat and the effect of administration of U-0521 (3,4-dihydroxy-2-methylpropiophenone)","volume":"158","author":"Giles","year":"1967","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0400","first-page":"353","article-title":"Inhibition of liver catechol-O-methyltransferase by flavanoids","volume":"201","author":"Gugler","year":"1973","journal-title":"Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0410","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(25)06681-5","article-title":"Catechol-O-methyltransferase:pharmacological aspects and physiological role","volume":"27","author":"Guldberg","year":"1975","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0420","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(02)02383-X","article-title":"Effects of entacapone and tolcapone on mitochondrial membrane potential","volume":"453","author":"Haasio","year":"2002","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0430","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1999.00036.x","article-title":"Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase","volume":"48","author":"Jorga","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0440","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s002280050490","article-title":"Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson\u2019s disease therapy","volume":"54","author":"Jorga","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0450","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0006-8993(92)91003-W","article-title":"Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study","volume":"587","author":"Kaakkola","year":"1992","journal-title":"Brain Res."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0460","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1021\/ja993084o","article-title":"Transition-state and ground-state structures and their interaction with the active-site residues in catechol-O-methyl transferase","volume":"122","author":"Kahn","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0470","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00199880","article-title":"Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone","volume":"46","author":"Ker\u00e4nen","year":"1994","journal-title":"Eur. J. Clin. Pharmacol"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0480","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neuropharm.2003.10.015","article-title":"Differences in toxicity of the catechol-O-methyltransferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells","volume":"46","author":"Korlipara","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0490","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1021\/ja992218v","article-title":"QM-FE and molecular dynamics calculations on catechol-O-methyltransferase: free energy of activation in the enzyme and in aqueous solution and regioselectivity of the enzyme-catalyzed reaction","volume":"122","author":"Kuhn","year":"2000","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0500","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/mol.59.2.393","article-title":"Molecular mechanisms controlling the rate and specificity of catechol-O-methylation by human soluble catechol-O-methyltransferase","volume":"59","author":"Lautala","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0510","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1021\/jm0580454","article-title":"Synthesis and biological evaluation of a novel series of \u201cortho-nitrated\u201d inhibitors of catechol-O-methyltransferase","volume":"48","author":"Learmonth","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0520","unstructured":"Learmonth, D.A., Kiss, L.E., Palma, P.N., Ferreira, H., and Soares-da-Silva, P. (2007). Nitrocatechol derivatives as COMT inhibitors. WO2007\/013830 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0530","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1021\/jm040848o","article-title":"Synthesis, biological evaluation, and molecular modeling Studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase","volume":"47","author":"Learmonth","year":"2004","journal-title":"J. Med. Chem"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0540","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/jm0109964","article-title":"Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase","volume":"45","author":"Learmonth","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0550","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0169-409X(96)00425-5","article-title":"Selection of developmentcandidates based on in vitro permeability measurements","volume":"23","author":"Lee","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0560","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/jm010980d","article-title":"Design and synthesis of a novel L-dopa-entacapone codrug","volume":"45","author":"Lepp\u00e4nen","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0570","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0960-894X(00)00384-X","article-title":"Synthesis of a water-soluble prodrug of entacapone","volume":"10","author":"Lepp\u00e4nen","year":"2000","journal-title":"Biorg. Med. Chem. Lett."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0580","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1211\/0022357011778025","article-title":"Synthesis and in-vitro\/in-vivo evaluation of orally administered entacapone prodrugs","volume":"53","author":"Lepp\u00e4nen","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0590","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1039\/B208690P","article-title":"Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity","volume":"1","author":"Lerner","year":"2003","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0600","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/1521-3773(20011105)40:21<4040::AID-ANIE4040>3.0.CO;2-C","article-title":"X-ray crystal structure of a bisubstrate inhibitor bound to enzyme catechol-O-methyltransferase: a dramatic effect of inhibitor preorganization on binding affinity","volume":"40","author":"Lerner","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0610","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00123380","article-title":"PLS modelling of structure-activity relationships of catechol-O-methyltransferase inhibitors","volume":"6","author":"Lotta","year":"1992","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0620","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/bi00013a008","article-title":"Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme","volume":"34","author":"Lotta","year":"1995","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/B978-0-12-381326-8.00006-5_bib0630","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1124\/dmd.106.010447","article-title":"Human metabolism of nebicapone (BIA 3-202), a novel catechol-O-methyltransferase inhibitor: characterization of in vitro glucuronidation","volume":"34","author":"Loureiro","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0640","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1021\/jm00278a004","article-title":"Sulfur analogues of dopamine and norepinephrine. Inhibition of catechol-O-methyltransferase","volume":"15","author":"Lutz","year":"1972","journal-title":"J. Med. Chem"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0650","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1080\/00397910701821077","article-title":"Convenient synthesis oftolcapone, a selective catechol-O-methyltransferase inhibitor","volume":"38","author":"Manikumar","year":"2008","journal-title":"Synth. Commun."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0660","unstructured":"Mantegazza, S., Allegrini, P., and Razzetti, G. (2008). Process for the preparation ofentacapone. US2008\/0146829 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0670","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/(SICI)1521-3765(20000317)6:6<971::AID-CHEM971>3.0.CO;2-0","article-title":"Structure-based design, synthesis and in vitro evaluation of bisubstrate inhibitors for catechol-O-methyltransferase (COMT)","volume":"6","author":"Masjost","year":"2000","journal-title":"Chem. Eur. J."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0680","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/0006-2952(66)90222-X","article-title":"Effects of long-term administration of pyrogallol on tissue catecholamine levels, monoamine oxidase and catechol-O-methyltransferase activities in the rat","volume":"15","author":"Ma\u00eetre","year":"1966","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0690","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1600-0773.1990.tb00756.x","article-title":"Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson\u2019s disease","volume":"66","author":"M\u00e4nnist\u00f6","year":"1990","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0700","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1476-5381.1992.tb09020.x","article-title":"Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat","volume":"105","author":"M\u00e4nnist","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0710","unstructured":"Mukarram, S.M., Khan, R.A., Yadav, R.P., and Shaikh, Z.G. (2008). Stable polymorphs of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide. US2008\/0004343."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0720","unstructured":"Nicolau, F.E., Ponce, A.M., Garcia, G.R., Benet-Buchholz, J., and Sola, L.C. (2008). New crystalline form of entacapone and process for its preparation. WO2008\/058992 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0730","unstructured":"Nicolau, F.E., Ponce, A.M., Garcia, G.R., Benet-Buchholz, J., and Sola, L.C. (2009). Process for preparing entacapone substantially free of Z-isomer, synthesis intermediates thereof and a new crystalline form. US2009\/0326062 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0740","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0014-2999(97)01431-3","article-title":"Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson\u2019s disease, does not impair mitochondrial energy production","volume":"340","author":"Nissinen","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0750","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0014-2999(88)90614-0","article-title":"Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat","volume":"153","author":"Nissinen","year":"1988","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0760","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF00173538","article-title":"Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone","volume":"346","author":"Nissinen","year":"1992","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0770","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/hlca.200690007","article-title":"The lipophilicity behaviour of three catechol-O-methyltransferase (COMT) inhibitors and simple analogues","volume":"89","author":"Novaroli","year":"2006","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0780","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and hepatotoxic effects","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/B978-0-12-381326-8.00006-5_bib0790","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/dmd.31.3.250","article-title":"Molecular modeling and metabolic studies of the interaction of catechol-O- methyltransferase and a new nitrocatechol inhibitor","volume":"31","author":"Palma","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0800","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/mol.106.023119","article-title":"Comparative study of ortho-and meta-nitrated inhibitors of catechol-O-methyltransferase. Interactions with the active site and regioselectivity of O-methylation","volume":"70","author":"Palma","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0810","first-page":"1270","article-title":"Bisubstrate inhibitors of the enzyme catechol-O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group","volume":"5","author":"Paulini","year":"2004","journal-title":"Chem. Biochem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0820","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1021\/jm00102a011","article-title":"Dihydroxynitrobenzaldehydes and hydroxymethoxynitrobenzaldehydes: synthesis and biological activity as catechol-O-methyltransferase inhibitors","volume":"35","author":"P\u00e9rez","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0830","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/0006-2952(93)90006-I","article-title":"Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitro benzylidene)-2,4-pentanedione","volume":"45","author":"P\u00e9rez","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0840","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/14756369409020195","article-title":"Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone","volume":"8","author":"P\u00e9rez","year":"1994","journal-title":"J. Enzyme Inhib."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0850","unstructured":"Pippuri, A.K., Honkanen, E.J., and Haarala, J.V. (1992). Stable polymorphic form of (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation. US Patent 5,135,950."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0860","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dof.1994.019.07.258368","article-title":"Entacapone","volume":"19","author":"Prous","year":"1994","journal-title":"Drugs Future"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0870","unstructured":"Pystynen, J., Ovaska, M., Vidgren, J., Lotta, T., and Yliperttula_ikonen, M. (2002). Coumarin derivatives with COMT inhibiting activity. WO2002\/02548 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0880","unstructured":"Ramakrishnan, A., Bathani, G., and Taduri, S. (2009). An improved process for preparation of (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)N,N-diethyl-2-propenamide polymorphic Form A. WO2009\/084031 A2."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0890","first-page":"171","article-title":"Catechol-O-methyltransferase and Parkinson\u2019s disease","volume":"40","author":"Reches","year":"1984","journal-title":"Adv. Neurol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0900","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0306-3623(96)00488-0","article-title":"Extraneuronal uptake inhibitor U-0521 decreases contractile responses in rat vas deferens","volume":"29","author":"Rice","year":"1997","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0910","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.bjp.0702474","article-title":"In vivo effects of new inhibitors of catechol-O-methyltransferase","volume":"126","author":"Rivas","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/B978-0-12-381326-8.00006-5_bib0920","first-page":"906","article-title":"Crystallization and preliminary crystallographic characterization of catechol-O-methyltransferase in complex with its co-substrate and an inhibitor","volume":"D57","author":"Rodrigues","year":"2001","journal-title":"Acta Crystallogr."},{"issue":"1","key":"10.1016\/B978-0-12-381326-8.00006-5_bib0930","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1107\/S1744309104031197","article-title":"Crystallization and preliminary X-ray diffraction studies of a catechol-O- methyltransferase\/inhibitor complex","volume":"61","author":"Rodrigues","year":"2005","journal-title":"Acta Crystallogr. F"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0940","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1600-0773.1964.tb01786.x","article-title":"Catechol-O-methyltransferase inhibitors. In vivo inhibition in mice","volume":"21","author":"Ross","year":"1964","journal-title":"Acta. Pharmacol. Toxicol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0950","unstructured":"Sanmarti, M.B., Rocabert, J.G., Nicolau, F.E., and Ponce, A.M. (2008). Process for the preparation of entacapone and intermediates thereof. WO2008\/119793 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0960","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/1098-2299(200004)49:4<238::AID-DDR2>3.0.CO;2-V","article-title":"Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone","volume":"49","author":"Savolainen","year":"2000","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0970","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0024-3205(00)00615-9","article-title":"Synthesis and in vitro\/in vivo evaluation of novel oral N-alkyl and N,N-dialkyl-carbamate esters of entacapone","volume":"67","author":"Savolainen","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0980","unstructured":"Semec, D.S., Marinkovic, M., Siljkovic, Z., and Horvat, M. (2007). New forms of active pharmaceutical ingredient. WO2007\/135406 A2."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib0990","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0009-8981(71)90373-1","article-title":"Dopa and 3-O-methyldopa in the cerebrospinal fluid of parkinsonism patients during treatment with oral L-dopa","volume":"31","author":"Sharpless","year":"1971","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1000","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1021\/jo9521920","article-title":"A mild and simple method for the preparation of isocyanates from aliphatic amines using trichloromethyl chloroformate. Synthesis of an isocyanate containing an activated disulfide","volume":"61","author":"Sigurdsson","year":"1996","journal-title":"J. Org. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00228-003-0680-5","article-title":"Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa\/benserazide","volume":"59","author":"Silveira","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/ci034189k","article-title":"CoMFA modeling of human catechol-O-methyltransferase enzyme kinetics","volume":"44","author":"Sipila","year":"2004","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/tx025569n","article-title":"In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1040","unstructured":"Tarur, V.T., Sathe, D.G., Bhise, N.B., Naidu, A.V., Aher, U.P., and Patil, S.S. (2008). Process for the preparation of highly pure (E)- N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (entacapone). US2008\/0319226 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/qsar.19890080304","article-title":"QSAR and binding model for inhibition of rat liver catechol-O-methyltransferase by 1,5-substituted-3,4-dihydroxybenzenes","volume":"8","author":"Taskinen","year":"1989","journal-title":"Quant. Struct. Act. Relat."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1060","unstructured":"Venkateswarlu, J., Reddy, A.V., Rajendiran, C., and Samjuddin, M.M. (2007).Methods for the preparation of entacapone. US2007\/0060767 A1."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/368354a0","article-title":"Crystal structure of catechol-O-methyltransferase","volume":"368","author":"Vidgren","year":"1994","journal-title":"Nature"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/prot.340110309","article-title":"Crystallisation and preliminary X-ray investigation of a recombinant form of catechol-O-methyltransferase","volume":"11","author":"Vidgren","year":"1991","journal-title":"Proteins"},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00169442","article-title":"CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure","volume":"342","author":"Waldmeier","year":"1990","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1100","first-page":"381","article-title":"Effects of the COMTinhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat","volume":"32","author":"Waldmeier","year":"1990","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0090-9556(25)07341-6","article-title":"Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans","volume":"21","author":"Wikberg","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1120","doi-asserted-by":"crossref","first-page":"9124","DOI":"10.1016\/S0021-9258(19)70536-5","article-title":"Stereochemical course of the transmethylation catalyzed by catechol-O-methyltransferase","volume":"255","author":"Woodard","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1130","unstructured":"Yadav, R.P., Shaikh, Z.G., and Mukarram, S.M. (2008). Processes for the preparation of a stable polymorphic form of entacapone. WO2008\/053304 A2."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1140","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1021\/ja971019d","article-title":"A theoretical examination of the factors controlling the catalytic efficiency of a transmethylation enzyme\u2014catechol-O-methyltransferase","volume":"119","author":"Zheng","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1150","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0090-9556(24)15181-1","article-title":"O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase","volume":"28","author":"Zhu","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1160","first-page":"375","article-title":"Inhibition of COMT in rat brain and extracellular tissues","volume":"32","author":"Z\u00fcrcher","year":"1990","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/B978-0-12-381326-8.00006-5_bib1170","first-page":"641","article-title":"Potent COMT inhibition by Ro40-7592 in the periphery and in the brain: preclinical and clinical findings","volume":"60","author":"Z\u00fcrcher","year":"1993","journal-title":"Adv. Neurol"}],"container-title":["International Review of Neurobiology","Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:59:05Z","timestamp":1740715145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123813268000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"ISBN":["9780123813268"],"references-count":117,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00006-5","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2010]]}}}